NO20006312L - Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragility - Google Patents
Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragilityInfo
- Publication number
- NO20006312L NO20006312L NO20006312A NO20006312A NO20006312L NO 20006312 L NO20006312 L NO 20006312L NO 20006312 A NO20006312 A NO 20006312A NO 20006312 A NO20006312 A NO 20006312A NO 20006312 L NO20006312 L NO 20006312L
- Authority
- NO
- Norway
- Prior art keywords
- ghs
- serms
- treatment
- growth hormone
- fragility
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000000333 selective estrogen receptor modulator Substances 0.000 title 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title 2
- 102000018997 Growth Hormone Human genes 0.000 title 1
- 108010051696 Growth Hormone Proteins 0.000 title 1
- 239000000122 growth hormone Substances 0.000 title 1
- 230000028327 secretion Effects 0.000 title 1
- 239000000021 stimulant Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Denne oppfinnelsen er rettet mot farmasøytiske kombinasjonsblandinger og fremgangsmåter inneholdende (-)-cis-6-fenyl-5-(4-(2-pyrrolidin-1-yl-etoksy)- fenyl)-5,6,7,8-tetrahydronaftalen-2-ol eller et farmasøytisk akesptabelt salt derav og2-amino-N-(2-(3a(R)-benzyl-2-metyl-3-okso-213,3a,4,6,7-heksahydropyra2olo- [4,3-c]pyridin-5-yl)-1(R)-benzyloksymetyl-2-oksoetyl)-isobutyramid eller et farma- søytisk akesptabelt salt derav, fremgangsmåter for anvendelse av slike blandinger og sett som inneholder slike blandinger. Blandingene kan anvendes for å be- handle muskelskjelett-skjørhet, inkludert osteoporose, osteoporotisk fraktur, lav benmasse, skjørhet, og lav muskelmasse.This invention is directed to pharmaceutical combination compositions and processes containing (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7,8-tetrahydronaphthalene 2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N- (2- (3a (R) -benzyl-2-methyl-3-oxo-213,3a, 4,6,7-hexahydropyr 2 -olo [4.3 (c] pyridin-5-yl) -1 (R) -benzyloxymethyl-2-oxoethyl) -isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compositions and sets containing such mixtures. The compositions can be used to treat musculoskeletal fragility, including osteoporosis, osteoporotic fracture, low bone mass, fragility, and low muscle mass.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8946998P | 1998-06-16 | 1998-06-16 | |
| PCT/IB1999/001117 WO1999065486A1 (en) | 1998-06-16 | 1999-06-16 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006312D0 NO20006312D0 (en) | 2000-12-12 |
| NO20006312L true NO20006312L (en) | 2000-12-12 |
Family
ID=22217825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006312A NO20006312L (en) | 1998-06-16 | 2000-12-12 | Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragility |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1087764A1 (en) |
| JP (1) | JP2002518326A (en) |
| KR (1) | KR20010052852A (en) |
| CN (1) | CN1301160A (en) |
| AP (1) | AP9901582A0 (en) |
| AR (1) | AR018869A1 (en) |
| AU (1) | AU4054799A (en) |
| BG (1) | BG105041A (en) |
| BR (1) | BR9911324A (en) |
| CA (1) | CA2335134A1 (en) |
| CO (1) | CO5070587A1 (en) |
| EA (1) | EA200001186A1 (en) |
| GT (1) | GT199900087A (en) |
| HN (1) | HN1999000097A (en) |
| HR (1) | HRP20000859A2 (en) |
| HU (1) | HUP0102505A3 (en) |
| ID (1) | ID27599A (en) |
| IL (1) | IL138630A0 (en) |
| IS (1) | IS5691A (en) |
| MA (1) | MA26652A1 (en) |
| NO (1) | NO20006312L (en) |
| OA (1) | OA11505A (en) |
| PA (1) | PA8475901A1 (en) |
| PE (1) | PE20000646A1 (en) |
| PL (1) | PL344981A1 (en) |
| SK (1) | SK18912000A3 (en) |
| TN (1) | TNSN99124A1 (en) |
| TR (1) | TR200003544T2 (en) |
| WO (1) | WO1999065486A1 (en) |
| ZA (1) | ZA993975B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360103A1 (en) * | 1999-02-08 | 2000-08-17 | Robert Sladek | Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha |
| DE60124616T2 (en) | 2000-05-08 | 2007-09-13 | Pfizer Products Inc., Groton | Enzymatic cleavage of selective modulators of the estrogen receptor |
| BR0113626A (en) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Sustained-Release Formulations for Growth Hormone Secretors |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| WO2006024931A2 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| CN101657436A (en) | 2007-02-09 | 2010-02-24 | 特兰齐姆制药公司 | macrocyclic ghrelin receptor modulators and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-06-15 ZA ZA9903975A patent/ZA993975B/en unknown
- 1999-06-15 AP APAP/P/1999/001582A patent/AP9901582A0/en unknown
- 1999-06-15 AR ARP990102848A patent/AR018869A1/en not_active Application Discontinuation
- 1999-06-15 HN HN1999000097A patent/HN1999000097A/en unknown
- 1999-06-15 PE PE1999000528A patent/PE20000646A1/en not_active Application Discontinuation
- 1999-06-15 PA PA19998475901A patent/PA8475901A1/en unknown
- 1999-06-16 BR BR9911324-4A patent/BR9911324A/en not_active Application Discontinuation
- 1999-06-16 IL IL13863099A patent/IL138630A0/en unknown
- 1999-06-16 WO PCT/IB1999/001117 patent/WO1999065486A1/en not_active Ceased
- 1999-06-16 EA EA200001186A patent/EA200001186A1/en unknown
- 1999-06-16 CN CN99806237A patent/CN1301160A/en active Pending
- 1999-06-16 AU AU40547/99A patent/AU4054799A/en not_active Abandoned
- 1999-06-16 ID IDW20002627A patent/ID27599A/en unknown
- 1999-06-16 GT GT199900087A patent/GT199900087A/en unknown
- 1999-06-16 JP JP2000554366A patent/JP2002518326A/en active Pending
- 1999-06-16 TN TNTNSN99124A patent/TNSN99124A1/en unknown
- 1999-06-16 HU HU0102505A patent/HUP0102505A3/en unknown
- 1999-06-16 CO CO99037622A patent/CO5070587A1/en unknown
- 1999-06-16 EP EP99923802A patent/EP1087764A1/en not_active Withdrawn
- 1999-06-16 HR HR20000859A patent/HRP20000859A2/en not_active Application Discontinuation
- 1999-06-16 KR KR1020007014186A patent/KR20010052852A/en not_active Ceased
- 1999-06-16 CA CA002335134A patent/CA2335134A1/en not_active Abandoned
- 1999-06-16 TR TR2000/03544T patent/TR200003544T2/en unknown
- 1999-06-16 MA MA25628A patent/MA26652A1/en unknown
- 1999-06-16 SK SK1891-2000A patent/SK18912000A3/en unknown
- 1999-06-16 PL PL99344981A patent/PL344981A1/en not_active Application Discontinuation
-
2000
- 2000-10-20 OA OA1200000290A patent/OA11505A/en unknown
- 2000-10-27 IS IS5691A patent/IS5691A/en unknown
- 2000-12-11 BG BG105041A patent/BG105041A/en unknown
- 2000-12-12 NO NO20006312A patent/NO20006312L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20000646A1 (en) | 2000-08-05 |
| TNSN99124A1 (en) | 2005-11-10 |
| NO20006312D0 (en) | 2000-12-12 |
| KR20010052852A (en) | 2001-06-25 |
| CN1301160A (en) | 2001-06-27 |
| TR200003544T2 (en) | 2001-04-20 |
| AP9901582A0 (en) | 1999-06-30 |
| OA11505A (en) | 2004-05-07 |
| ZA993975B (en) | 2000-12-15 |
| GT199900087A (en) | 2000-12-07 |
| AR018869A1 (en) | 2001-12-12 |
| MA26652A1 (en) | 2004-12-20 |
| SK18912000A3 (en) | 2001-10-08 |
| HUP0102505A2 (en) | 2001-11-28 |
| IL138630A0 (en) | 2001-10-31 |
| BG105041A (en) | 2001-08-31 |
| CA2335134A1 (en) | 1999-12-23 |
| ID27599A (en) | 2001-04-12 |
| IS5691A (en) | 2000-10-27 |
| HN1999000097A (en) | 1999-11-03 |
| EA200001186A1 (en) | 2001-06-25 |
| HUP0102505A3 (en) | 2002-12-28 |
| EP1087764A1 (en) | 2001-04-04 |
| AU4054799A (en) | 2000-01-05 |
| PA8475901A1 (en) | 2000-05-24 |
| WO1999065486A1 (en) | 1999-12-23 |
| BR9911324A (en) | 2001-04-03 |
| HRP20000859A2 (en) | 2001-04-30 |
| CO5070587A1 (en) | 2001-08-28 |
| PL344981A1 (en) | 2001-11-19 |
| JP2002518326A (en) | 2002-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU18400A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| NO20040331L (en) | Medicines for diseases with bone loss that have Eragonist as the active ingredient | |
| EP0911321A3 (en) | Compounds for the treatment of osteoporosis | |
| BR9714155A (en) | Prevention of bone mass loss and replacement by certain prostaglandin agonists. | |
| DE60037836D1 (en) | ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis | |
| WO1998058911A3 (en) | Prostaglandin agonists | |
| NO20006312L (en) | Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragility | |
| DK217588D0 (en) | 17BETA- (CYCLOPROPYLAMINO) -ANDROST-5-EN-3BETA OLDER DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS | |
| BG105125A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| NO20006381L (en) | Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretion agents | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| NZ504051A (en) | Crystalline polymorphs of 1,3-di-cyclopropylmethyl-8-amino xanthine (cypamfylline), and the use of these compounds for treating PDE4 or TNF mediated diseases | |
| NO980375L (en) | Human MP52 Arg protein | |
| Schuind et al. | Hyperostotic macrodactyly | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| SU1759409A1 (en) | Compression-distraction device | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| TODANI | A follow-up study of the subtrochanteric osteotomy for the treatment of the irreducible congenital dislocation of the hip | |
| Garg et al. | Long-term Functional Outcome in Fractures of the Lower End Radius in Young Adults Treated by Static External Fixator | |
| Ikemoto et al. | Treatment of Fracture-Dislocation of the Ankle | |
| Whitman | TREATMENT OF FRACTURES OF NECK OF FEMUR | |
| UA28851A (en) | Method of operative treatment of the tibia distal epiphysis fructures | |
| Hajime et al. | The Improvement of the Upper Extremity Function in Cerebral Palsy | |
| Fukushima et al. | The Y-shaped Plate for the Fractures around the Joint | |
| Zhuber et al. | The Orthopedic Treatment of Patients with Apallic Syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |